Here is some more research info on a patch which sounds very...

Here is some more research info on a patch which sounds very similar to ours and is about to go into production very soon....

About Zelrix
Zelrix is a novel migraine therapy in clinical development for the treatment of acute migraine. If approved for marketing, Zelrix would be the first and only transdermal patch for migraine patients. Zelrix utilizes a proprietary state-of-the-art transdermal delivery system, SmartRelief, to deliver sumatriptan, the most widely prescribed migraine therapy in the United States, in a rapid but controlled manner.

Zelrix was designed to address key limitations of existing therapies. Oral therapies are often difficult to take when patients are nauseated during migraine attacks and can lead to inconsistent efficacy. In addition, side effects associated with peak plasma concentrations limit patients? ability or willingness to take certain treatments. Based upon clinical results to date, Zelrix could offer patients a treatment that allows them to treat their migraine on time every time, regardless of gastrointestinal symptoms, in a well-tolerated manner. NuPathe expects to submit an NDA for Zelrix in 2010.

About SmartRelief
SmartRelief is a proprietary iontophoretic system combining modern electronics with state‐of‐the‐art formulation and pharmaceutics technology. Iontophoresis is a non‐invasive method for transporting a molecule through the skin by means of a mild electrical current. The electrical current carries the charged molecule from the patch across the skin. Once across, the drug is rapidly absorbed by the microvascular and distributed systemically.